Patient Leaflet Updated 25-Aug-2023 | Gilead Sciences Ltd
Odefsey 200 mg/25 mg/25 mg film-coated tablets
Odefsey 200 mg/25 mg/25 mg film-coated tablets
emtricitabine/rilpivirine/tenofovir alafenamide
1. What Odefsey is and what it is used for
2. What you need to know before you take Odefsey
3. How to take Odefsey
4. Possible side effects
5. How to store Odefsey
6. Contents of the pack and other information
Odefsey is an antiviral medicine used to treat infection by the Human Immunodeficiency Virus (HIV). It is a single tablet that contains a combination of three active substances: emtricitabine, rilpivirine and tenofovir alafenamide. Each of these active substances works by interfering with an enzyme called ‘reverse transcriptase’, which is essential for the HIV-1 virus to multiply.
Odefsey reduces the amount of HIV in your body. This will improve your immune system and reduce the risk of developing illnesses linked to HIV infection.
Odefsey is used in adults and adolescents aged 12 years and older, who weigh at least 35 kg.
You must remain under the care of your doctor while taking Odefsey.
This medicine is not a cure for HIV infection. While taking Odefsey you may still develop infections or other illnesses associated with HIV infection.
Once you start taking Odefsey, look out for:
There is a possibility that you may experience kidney problems when taking Odefsey over a long period of time (see Warnings and precautions).
Do not give this medicine to children aged 11 years or under, or weighing less than 35 kg. The use of Odefsey in children aged 11 years or under or weighing less than 35 kg has not yet been studied.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Odefsey may interact with other medicines. As a result, the amounts of Odefsey or other medicines in your blood may be affected. This may stop your medicines from working properly, or may make any side effects worse. In some cases, your doctor may need to adjust your dose or check your blood levels.
Talk to your doctor if you are taking:
Ask your doctor or pharmacist for advice before taking any medicine when pregnant.
If you have taken Odefsey during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took nucleoside reverse transcriptase inhibitors (NRTIs) during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.
Do not breast-feed during treatment with Odefsey. This is because some of the active substances in this medicine pass into human breast milk.
Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk.
If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.
Do not drive or operate machines if you feel tired, sleepy or dizzy after taking your medicine.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Adults: one tablet each day with food
Adolescents 12 years of age and older, who weigh at least 35 kg: one tablet each day with food
It is important to take Odefsey with food to get the right levels of active substance in your body. A nutritional drink alone does not replace food.
It is recommended not to chew, crush or split the tablet due to the bitter taste.
If you are taking an antacid such as aluminium/magnesium hydroxide, or calcium carbonate, take it at least 2 hours before or at least 4 hours after Odefsey.
If you are taking an H2-antagonist such as famotidine, cimetidine, nizatidine or ranitidine, take it at least 12 hours before or at least 4 hours after Odefsey. H2-antagonists can only be taken once a day if you take Odefsey. H2-antagonists should not be taken twice a day. Talk to your doctor about an alternative regimen.
If you are on dialysis, take your daily dose of Odefsey following completion of dialysis.
If you accidentally take more than the recommended dose of Odefsey you may be at increased risk of experiencing possible side effects with this medicine (see section 4, Possible side effects).
Contact your doctor or nearest emergency department immediately for advice. Keep or take the tablet bottle with you so that you can easily describe what you have taken.
It is important not to miss a dose of Odefsey.
If you do miss a dose:
If you vomit less than 4 hours after taking Odefsey, take another tablet with food. If you vomit more than 4 hours after taking Odefsey you do not need to take another tablet until your next regularly scheduled tablet.
Do not stop taking Odefsey without talking to your doctor. Stopping Odefsey can seriously affect your response to future treatment. If Odefsey is stopped for any reason, speak to your doctor before you restart taking Odefsey tablets.
When your supply of Odefsey starts to run low, get more from your doctor or pharmacist. This is very important because the amount of virus may start to increase if the medicine is stopped for even a short time. The disease may then become harder to treat.
If you have both HIV infection and hepatitis B, it is especially important not to stop your Odefsey treatment without talking to your doctor first. You may require blood tests for several months after stopping treatment. In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your hepatitis, which may be life-threatening.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common side effects
(may affect more than 1 in 10 people)
Tests may also show:
Common side effects
(may affect up to 1 in 10 people)
Tests may also show:
Uncommon side effects
(may affect up to 1 in 100 people)
The frequency of the following side effects is not known (frequency cannot be estimated from the available data).
During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and bottle after {EXP}. The expiry date refers to the last day of that month.
Store in the original package in order to protect from moisture. Keep the bottle tightly closed.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substances are emtricitabine, rilpivirine and tenofovir alafenamide. Each Odefsey tablet contains 200 mg of emtricitabine, rilpivirine hydrochloride equivalent to 25 mg of rilpivirine and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide.
Tablet core:
Croscarmellose sodium, lactose (as monohydrate), magnesium stearate, microcrystalline cellulose, polysorbate 20, povidone.
Film-coating:
Macrogol, polyvinyl alcohol, talc, titanium dioxide (E171), iron oxide black (E172).
Odefsey is a grey, capsule-shaped, film-coated tablet debossed on one side with “GSI” and “255” on the other side. Odefsey comes in bottles of 30 tablets and in packs made up of 3 bottles, each containing 30 tablets. Each bottle contains a silica gel desiccant that must be kept in the bottle to help protect your tablets. The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.
Not all pack sizes may be marketed.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in 06/2023.
ODE - 50108
280 High Holborn, London, WC1V 7EE, UK
+44 (0)203 681 4681
08000 113 700 (UK)
+44 (0)203 681 4500
+353 1 291 3580 (Ireland)
+353 214 825 999 (Ireland)